Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4100+0.0040 (+0.99%)
At close: 04:00PM EDT
0.4305 +0.02 (+5.00%)
After hours: 04:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.4060
Open0.4060
Bid0.3950 x 1100
Ask0.4100 x 4000
Day's Range0.3802 - 0.4179
52 Week Range0.3802 - 4.4000
Volume106,471
Avg. Volume65,497
Market Cap13.226M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-1.0440
Earnings DateDec 21, 2022 - Dec 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBSE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuBase Therapeutics, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference

    PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022. Details of the presentation a

  • GlobeNewswire

    NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

    Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting a differentiated whole-body treatment solution for DM1Management decision to conduct additional preclinical studies expected to further strengthen the planned Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA)

  • Simply Wall St.

    We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Advertisement
Advertisement